ReviewAdvances in chronic kidney disease2010
Treatment strategies and clinical trial design in ADPKD.
Review in Advances in chronic kidney disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2014Trial
- Cross-Species Insights into Autosomal Dominant Polycystic Kidney Disease: Provide an Alternative View on Research Advancement.International journal of molecular sciences · 2024Review
- Article
- Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions.Journal of cellular physiology · 2019Review
- Article
- The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease.Experimental biology and medicine (Maywood, N.J.) · 2018Article
- Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2018Article
- Should kidney volume be used as an indicator of surgical occasion for patients with autosomal dominant polycystic kidney disease?Medicine · 2018Observational
- Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.The Journal of clinical investigation · 2017Article
- RAPAMYCIN INCREASES LENGTH AND MECHANOSENSORY FUNCTION OF PRIMARY CILIA IN RENAL EPITHELIAL AND VASCULAR ENDOTHELIAL CELLS.International education and research journal · 2016Article
- Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease.PloS one · 2016Article
- Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.Journal of translational medicine · 2015Article
- Novel treatments of autosomal dominant polycystic kidney disease.Clinical journal of the American Society of Nephrology : CJASN · 2014Article
- Prophages in enterococcal isolates from renal transplant recipients: renal failure etiologies promote selection of strains.BioMed research international · 2014Article
- Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.American journal of physiology. Renal physiology · 2013Review
- CFTR inhibitors.Current pharmaceutical design · 2013Review
- Caffeine intake by patients with autosomal dominant polycystic kidney disease.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2012Article
- Educational paper: ciliopathies.European journal of pediatrics · 2012Review
- Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic.BMC nephrology · 2012Article
- Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease.Journal of clinical immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
More frequent utilization and continuous improvement of imaging techniques has enhanced appreciation of the high phenotypic variability of autosomal dominant polycystic kidney disease, improved understanding of its natural history, and facilitated the observation of its structural progression. At the same time, identification of the PKD1 and PKD2 genes has provided clues to how the disease develops when they (genetic mechanisms) and their encoded proteins (molecular mechanisms) are disrupted. Interventions designed to rectify downstream effects of these disruptions have been examined in animal models, and some are currently tested in clinical trials. Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.